We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
Solid Biosciences Inc | NASDAQ:SLDB | NASDAQ | Common Stock |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.09 | 1.19% | 7.63 | 7.11 | 7.85 | 7.72 | 7.22 | 7.70 | 145,572 | 01:00:00 |
Details of the MDA presentation:
Session Title: IGNITE-DMD: Phase I/II Ascending Dose Study of Single IV Infusion of SGT-001 Microdystrophin Gene Therapy for DMD: One Year Efficacy and Safety Results
Session Date: Thursday, March 18, 2021 4 PM ET
Registration: The public must be registered to view live-broadcast sessions, on-demand videos, virtual networking sessions, exhibits and poster sessions.
To register, visit: https://mdavirtualconference.org/en/registration
Symposium with Key Opinion LeadersAlso, on March 18, Solid Biosciences will sponsor a symposium, “Real World Outcome Measures in Duchenne Muscular Dystrophy: Current and Novel Assessments of Meaningful Patient Benefit” at 12 PM ET. The symposium will feature:
Registration: The public must be registered to view live-broadcast sessions, on-demand videos, virtual networking sessions, exhibits and poster sessions.
Company Conference CallSolid Biosciences’ management will host a conference call beginning at 4:30 PM ET on Monday, March 15, 2021 to discuss the IGNITE DMD data that will be presented at the MDA Conference, the Company’s fourth quarter and full year 2020 financial results and recent business developments.
A live webcast of the call will be available on the Company's website at www.solidbio.com under the “News & Events” tab in the Investor Relations section, or by clicking here. Participants may also access the call, by dialing 866-763-0341 for domestic callers or 703-871-3818 for international callers, referencing conference ID# 1669808.
The archived webcast will be available in the “News and Events” section of the Company's website.
About Solid BiosciencesSolid Biosciences is a life sciences company focused on advancing transformative treatments to improve the lives of patients living with Duchenne. Disease-focused and founded by a family directly impacted by Duchenne, our mandate is simple yet comprehensive – work to address the disease at its core by correcting the underlying mutation that causes Duchenne with our lead gene therapy candidate, SGT-001. For more information, please visit www.solidbio.com.
Investor Contact:David CareyFINN Partners212-867-1768David.Carey@finnpartners.com
Media Contact:Erich SandovalFINN Partners917-497-2867Erich.Sandoval@finnpartners.com
1 Year Solid Biosciences Chart |
1 Month Solid Biosciences Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions